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SummaryGATA binding protein 4 (GATA4) establishes jejunal enterocyte identity and represses ileal enterocyte identity in the intestine, likely through direct activation and repression of expression of key regional-specifying genes. One important GATA4 target is fibroblast growth factor 15, a key regulator of enterohepatic bile acid cycling.

The small intestine is composed of duodenum, jejunum, and ileum. Enterocytes within each perform specialized functions dictated by their position along the cephalocaudal axis to mediate digestion and absorption of nutrients, vitamins, and fluids to sustain growth, hydration, and electrolyte balance. Duodenal enterocytes are specialized to complete the digestive process.[@bib1] Enzymes secreted from the pancreas as well as bile synthesized by liver and stored by the gall bladder enter the duodenum and combine with enzymes secreted by the duodenal enterocytes to facilitate digestion. Jejunal enterocytes accomplish the bulk of nutrient uptake by absorbing digestive products, namely lipid--bile acid emulsions, sugars, and oligopeptides/amino acids.[@bib1], [@bib2] In addition to absorbing vitamin B12, ileal enterocytes play a critical role in maintaining the enterohepatic circulation of bile acids and in regulating bile acid metabolism.[@bib1], [@bib2] Ileal enterocytes absorb bile acids from the intestinal lumen, and bile acids travel via the portal circulation from the intestine to the liver, where they are taken up and re-secreted into bile. Uptake of bile acids by ileal enterocytes activates farnesoid X receptor (FXR)-mediated transactivation of genes encoding proteins required for enterocyte bile acid transport including *fatty acid binding protein 6* (*Fabp6*), *solute carrier 51a (Slc51a)*, *Slc51b* and the secreted enterokine *fibroblast growth factor 15/19 (Fgf15/19)*.[@bib3], [@bib4], [@bib5], [@bib6] Binding of FGF15/19 to its receptors on hepatocytes represses expression of *cytochrome P450 family 7 subfamily A member 1* (*Cyp7a1*), which encodes the rate-limiting enzyme in conversion of cholesterol to bile acids, to control hepatic bile acid synthesis.[@bib4], [@bib5] Moreover, bile acids and FGF15/19 may function in the regulation of energy expenditure and lipid and carbohydrate metabolism.[@bib7], [@bib8], [@bib9] As such, the importance of bile acid enterohepatic cycling and homeostasis extends beyond intestinal function, and defects in enterohepatic FGF15/19 signaling have been linked to human diseases including cholestatic liver disease, nonalcoholic fatty liver disease, type 2 diabetes, metabolic syndrome, Crohn's disease, bile acid malabsorption, and bile acid diarrhea.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11]

Disruption of enterocyte functions caused by Crohn's disease and other inflammatory bowel diseases, intestinal tumors, trauma, necrotizing enterocolitis, and congenital defects, along with surgical interventions used to treat these disorders, can result in intestinal failure or short-bowel syndrome (SBS).[@bib12], [@bib13] High morbidity and mortality are associated with SBS, and the economic and quality-of-life costs for SBS patients are high.[@bib12], [@bib14] Better SBS therapies are needed, particularly interventions that restore lost function to remaining intestinal tissue, as well as novel tissue engineering approaches to overcome small-bowel organ shortages for transplant. To make these advances a reality, it will be necessary to understand how duodenal, jejunal, and ileal epithelial identities are patterned along the cephalocaudal axis of the small intestine. Currently, the molecular mechanisms underlying establishment and maintenance of enterocyte populations with regionally defined functions are delineated poorly. Extrinsic cues such as luminal contents and hormones can influence expression of regional-specific enterocyte markers, but tissue transplantation and isograft experiments show that regionalized gene expression programs are intrinsic to the epithelium.[@bib15], [@bib16], [@bib17] More recently, using a long-term organoid culture model, Middendorp et al[@bib18] showed that adult small intestinal stem cells maintain regional identity and regionally defined gene expression programs in a cell autonomous manner. We propose that the repertoire of transcription factors expressed in duodenal, jejunal, and ileal enterocytes drives patterning by activating and repressing expression of the set of downstream targets defining each region. GATA binding protein 4 (GATA4), a zinc-finger--containing transcription factor with a spatially restricted expression pattern along the cephalocaudal axis of the small intestine, represents one such factor.

GATA4 is expressed in enterocytes of the duodenal and jejunal epithelium but absent from enterocytes of the ileal epithelium.[@bib19], [@bib20], [@bib21] Studies of mouse intestinal development show that GATA4 initially is expressed throughout the developing intestinal epithelium and that it becomes excluded from the ileal domain relatively early at embryonic day (E)12.5--13.5.[@bib22] GATA4 plays a role in early intestinal development, regulating intestinal epithelial cell proliferation.[@bib23] Specifically, GATA4 deletion in the intestinal epithelium via Sonic hedgehog--Cre transiently reduces cellular proliferation in the intestinal epithelium (E10.5--E11.5), resulting in a shorter intestine with decreased epithelial girth. Furthermore, the onset of villus morphogenesis is delayed in the intestine of *Gata4 Sonic hedgehog--Cre* conditional knockout embryos, perhaps because of reduced epithelial cell proliferation, and villus structure is abnormal. In adult mice, GATA4 is essential for jejunal function.[@bib19], [@bib21] Elimination of GATA4 from the intestinal epithelium using Villin-Cre causes a global shift in regional identity within the jejunum.[@bib21] In the absence of jejunal GATA4, expression of a wide array of jejunal-specific genes is lost, including expression of genes encoding proteins with important roles in uptake, transport, and processing of cholesterol and lipids.[@bib21] Moreover, expression of numerous ileal-specific genes is gained, including expression of genes encoding proteins required for bile acid absorption.[@bib21] These sweeping changes in gene expression from a jejunal to an ileal pattern also have important functional consequences, disrupting the normal spatial pattern of the digestive process and causing malabsorption of dietary fat and cholesterol.[@bib21] Deletion of *Gata4* in the jejunal epithelium of adult mice via an inducible conditional knockout strategy similarly alters jejunal gene expression, shifting it away from a jejunal profile and toward an ileal profile.[@bib19] Comparison of jejunal phenotypes between *Gata4* and *Gata6* *Villin-Cre* conditional knockout mice further indicates that GATA control of jejunal-ileal epithelial identity is a GATA4-specific function because expression of key jejunal and ileal markers is not altered in GATA6-deficient jejunum.[@bib22], [@bib24] Taken together, these studies show that GATA4 is necessary for execution of the enterocyte gene expression program in the jejunum.

The goal of the present study was to test the hypothesis that GATA4 is sufficient to confer jejunal fate within the intestinal epithelium. To test this hypothesis, we used a conditional knock-in approach to generate mice expressing GATA4 in the ileal epithelium, where it normally is absent. If GATA4 is sufficient to drive jejunal identity, the ileal enterocyte gene expression profile should shift from ileal to jejunal. Indeed, we found that the global gene expression profile of GATA4-expressing ileal epithelium differed significantly from control ileal epithelium, aligning more closely with jejunum rather than ileum. We also observed overlap between GATA4-expressing ileum and duodenum, suggesting that ectopic GATA4 expression within the ileum can induce duodenal gene expression, thereby conferring a more proximal-type intestinal identity with both jejunal and duodenal character. Focusing on jejunal vs ileal identity, gene expression changes in the presence or absence of GATA4 and GATA4 chromatin immunoprecipitation experiments strongly suggest that GATA4 patterns regional-specific functions by directly activating expression of genes defining jejunum and by directly repressing expression of genes defining ileum. We further show that enterohepatic signaling was altered in mice expressing GATA4 in the ileum. Taken together, these data extend our understanding of GATA4 as a crucial dominant molecular determinant of enterocyte identity and regulator of enterohepatic signaling. Considering that GATA4 is necessary and sufficient to promote jejunal identity and repress ileal identity, GATA4 represents a logical candidate to consider as a therapeutic target for intestinal failure.

Materials and Methods {#sec1}
=====================

Animals {#sec1.1}
-------

To generate *Gata4* conditional knock-in mice (*Gt(ROSA)26Sor*^*tm1(Gata4)Bat*^, MGI: [5707906](mgi:5707906){#intref0020}), the coding sequence of mouse *Gata4* was amplified by polymerase chain reaction (PCR) using the Expand High Fidelity PCR system (Roche, Madison, WI). The forward primer contained a *XhoI* restriction site, and the reverse primer contained a *SacI* restriction site for cloning into the *XhoI/SacI* sites in the multiple cloning site of the pBigT plasmid[@bib25] to create pBigT-*Gata4* ([Figure 1](#fig1){ref-type="fig"}*A*). Primer sequences are listed in [Table 1](#tbl1){ref-type="table"}. A cassette containing the adenovirus splice acceptor (SA), a *loxP*-flanked phosphoglycerate kinase (PGK) promoter-neomycin resistance gene (Neo)-3xSV40 polyadenylation (pA) (designated LNL), the *Gata4* coding sequence, and the bovine growth hormone polyadenylation (pA) sequence was excised from pBigT-*Gata4* with *PacI* and *AscI*. This fragment was inserted into the *PacI/AscI* sites in the plasmid pROSA26PA[@bib25] to create the pROSA26PA-*Gata4* targeting vector ([Figure 1](#fig1){ref-type="fig"}*A*). Targeting vector, linearized by digestion with *Asp718*, was introduced into R1 mouse embryonic stem cells by electroporation.[@bib26] Embryonic stem cell colonies resistant to 350 μg/mL active G418 (Life Technologies, Grand Island, NY) were genotyped by Southern blot and PCR. Chimeric animals were generated by aggregation of CD-1 morulae with R1 mouse embryonic stem cells containing the modified allele (*Gt(ROSA)26Sor*^*tm1(Gata4)Bat*^, designated *ROSA26*^*lnlG4*^), as described previously.[@bib27] The modified *ROSA26*^*lnlG4*^ allele was propagated through the germline by breeding chimeras to CD-1 mice, and germline transmission of the modified *ROSA26*^*lnlG4*^ allele was confirmed by Southern blot ([Figure 1](#fig1){ref-type="fig"}*B*). Heterozygous *ROSA26*^*lnlG4/+*^ animals were crossed to generate homozygous *ROSA26*^*lnlG4/lnlG4*^ mice that were crossed with *Villin-Cre* (*Tg(Vil-cre)997Gum*) mice[@bib28] to generate heterozygous *Gata4* conditional knock-in mice (*Gata4* cKI) with the genotype *ROSA26*^*lnlG4/+*^*Villin-Cre*. For conditional knockout of *Gata4* in the jejunum, *Gata4*^*loxP*^ mice *(Gata4*^*tm1.1Sad*^*)*[@bib29] were crossed with *Villin-Cre* mice to produce *Gata4*^*loxP/loxP*^*Villin-Cre* mice. CD-1 mice (Charles River Laboratories, Wilmington, MA) were used as wild-type control. For biotin-mediated chromatin immunoprecipitation (bio-ChIP) studies, the *Gata4*^*flbio/flbio*^(*Gata4*^*tm3.1Wtp*^) and *ROSA26*^*BirA*^*(Gt*(ROSA)*26Sor*^*Tm1\[birA\]Mejr*^*)* mouse lines were used to generate *Gata4*^*flbio/flbio*^*::ROSA26*^*BirA/BirA*^ and *ROSA26*^*BirA/BirA*^ mice for bio-ChIP.[@bib30], [@bib31] Primers used for PCR genotyping of ear punch DNA are listed in [Table 1](#tbl1){ref-type="table"}. Studies with *ROSA26*^*lnlG4/+*^, *ROSA26*^*lnlG4/+*^*Villin-Cre*, *Gata4*^*loxP/loxP*^*Villin-Cre*, and CD-1 mice were performed with 6- to 8-week-old male mice. Studies with *Gata4*^*flbio/flbio*^*::ROSA26*^*BirA/BirA*^ and *ROSA26*^*BirA/BirA*^ were performed with epithelial cells from 4- to 6-month-old male mice. In all studies, duodenum was collected from no more than 8 cm adjacent to the stomach, jejunum was collected 10 cm from the stomach, and ileum was collected from no more than 5 cm adjacent to the cecum. The Medical College of Wisconsin Institutional Animal Care and Use Committee approved all animal procedures.

Southern Blot {#sec1.2}
-------------

Genomic DNA was isolated from mouse tails by digesting tissue in lysis buffer (4 mol/L urea, 10 mmol/L 1,2-Cyclohexylenedinitrilotetraacetic acid, 0.5% sarkosyl, 0.1 mol/L Tris HCl pH 8.0, 0.2 mol/L NaCl, and 2 μg proteinase K) at 55°C overnight followed by DNA precipitation. Southern blot was performed using standard conditions with *EcoRV* or *BamHI* digested DNA and probes illustrated in [Figure 1](#fig1){ref-type="fig"}*A*. Probe 1 was generated by PCR using primers listed in [Table 1](#tbl1){ref-type="table"} and the plasmid pROSA26-5' as the template.[@bib25], [@bib32] Probe 2 was generated by isolating a 381--base pair (bp) product from *HindIII* digestion of the plasmid pROSA26PA.[@bib25]

Epithelial Cell Isolation {#sec1.3}
-------------------------

Epithelial cells (crypt and villus) were isolated from duodenum, jejunum, and ileum following a protocol modified from Guo et al[@bib33] in 2009. Briefly, intestine was everted on a glass rod and placed in a conical tube containing a balanced salt solution (BSS) buffer with EDTA (1.5 mmol/L KCl, 96 mmol/L NaCl, 27 mmol/L sodium citrate, 8 mmol/L KH~2~PO~4~, 5.6 mmol/L Na~2~HPO~4~, and 15 mmol/L EDTA) with 200 μmol/L phenylmethylsulfonyl fluoride. After 25 minutes of vortexing at 4°C to release epithelial cells from villi and crypts, remaining mesenchymal and muscle tissues were removed. Epithelial cell isolates, containing both crypt and villus cells, were pelleted by centrifuging at 2000 rpm for 10 minutes at 4°C. Cells were washed twice with 1× phosphate-buffered saline containing 200 μmol/L phenylmethylsulfonyl fluoride and used for RNA or protein extraction.

Reverse-Transcription PCR {#sec1.4}
-------------------------

Total RNA was isolated from duodenal, jejunal, and ileal epithelial cells and from liver (RNeasy; Qiagen, Valencia, CA). Complementary DNA (cDNA) was generated from DNase-treated RNA as previously described.[@bib34], [@bib35] Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and RT-PCR using \[α-^32^P\] deoxyadenosine triphosphate (dATP) were performed as previously described.[@bib22], [@bib35], [@bib36] For qRT-PCR and radioactive RT-PCR, *glyceraldehyde 3 phosphate dehydrogense* (*Gapdh*) expression was used for normalization. A Storm820 Phosphor Imager (Amersham Biosciences, Pittsburgh, PA) was used to quantitate band intensities from radioactive RT-PCR. Each gene was assayed in at least 3 independent experiments. For TaqMan (Thermo Scientific, Rockford, IL) qRT-PCR of gene expression in duodenum and jejunal epithelium, cDNA from 3 control *ROSA26*^*lnlG4/+*^ and 3 *Gata4* cKI *ROSA26*^*lnlG4/+*^*Villin-Cre* mice were used. For TaqMan qRT-PCR of gene expression in ileal epithelium, cDNA from 5 control *ROSA26*^*lnlG4/+*^ and 6 *Gata4* cKI *ROSA26*^*lnlG4/+*^*Villin-Cre* mice were used. For RT-PCR with \[α-^32^P\] dATP to determine gene expression in ileal epithelium, cDNA from 3 control *ROSA26*^*lnlG4/+*^ and 3 *Gata4* cKI *ROSA26*^*lnlG4/+*^*Villin-Cre* mice were used. For all RT-PCR of gene expression in jejunal epithelium (TaqMan qRT-PCR and RT-PCR with \[α-^32^P\] dATP), cDNA from 3 control *Gata4*^*loxP/loxP*^ and 3 mutant *Gata4*^*loxP/loxP*^*Villin-Cre* mice were used. Statistical analysis was performed using StatPlus Software (AnalystSoft Inc, Walnut, CA). Error bars represent the SEM. *P* values were determined by 2-sample Student *t* test. [Table 1](#tbl1){ref-type="table"} contains primer sequences and TaqMan assay identifiers.

Histochemistry, Immunohistochemistry, and Immunofluorescence {#sec1.5}
------------------------------------------------------------

Duodenal, jejunal, and ileal tissue (0.5 cm) was fixed in 4% paraformaldehyde overnight, processed, and paraffin-embedded. H&E staining was performed per standard procedures. Citric acid antigen retrieval was performed for immunohistochemistry. Staining was visualized using R.T.U. Vectastain Elite ABC reagent (Vector Labs, Burlingame, CA) and a Metal Enhanced DAB substrate kit (Thermo Scientific, Rockford, IL). For immunofluorescence, fresh-frozen sections were fixed with 4% paraformaldehyde before antibody staining. Sections from at least 3 control (*ROSA26*^*lnlG4*/+^) and 3 *Gata4* cKI animals (*ROSA26*^*lnlG4/+*^ *Villin-Cre*) were analyzed. Histochemistry and immunohistochemistry slides were scanned using a NanoZoomer slide scanner (Hamamatsu, Bridgewater, NJ), and images from scanned slides were captured using NDP.view 2 software (Hamamatsu). Fluorescent images were captured on a Nikon Eclipse 80i microscope (Melville, NY), using a Nikon digital smart DS-QiMc camera. [Table 2](#tbl2){ref-type="table"} shows antibody details.

Immunoblotting {#sec1.6}
--------------

Nuclear and cytoplasmic protein extracts were prepared from duodenal, jejunal, and ileal epithelial isolates from control *ROSA26*^*lnlG4*/+^ and *Gata4* cKI (*ROSA26*^*lnlG4/+*^*Villin-Cre*) mice using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) and HALT Protease and Phosphatase Inhibitor cocktails without EDTA (Thermo Scientific). Whole-cell lysates were prepared from jejunal and ileal epithelial isolates from control *ROSA26*^*lnlG4*/+^ and *Gata4* cKI (*ROSA26*^*lnlG4/+*^*Villin-Cre*) mice using a 1× NP40 lysis buffer (0.5% NP40, 50 mmol/L Tris pH 8, 10% glycerol, 0.1 mmol/L EDTA pH 8, and 250 mmol/L NaCl) containing HALT Protease and Phosphatase Inhibitor cocktails without EDTA (Thermo Scientific, Rockford, IL). Nuclear proteins (5 μg), cytoplasmic proteins (25 μg), or whole-cell lysates (10 μg) were separated using Nu-PAGE Bis-Tris 4%--12% gradient gels (Invitrogen, Carlsbad, CA), and transferred to an Immobilon-FL polyvinylidene difluoride membrane (Millipore, Darmstadt, Germany). Immunoblots were visualized using an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE) and quantitated using National Institutes of Health ImageJ software (Bethesda, MD). [Table 2](#tbl2){ref-type="table"} shows antibody details.

Oligonucleotide Array Analysis {#sec1.7}
------------------------------

Total RNA was extracted from duodenal, jejunal, or ileal epithelial cells (RNeasy; Qiagen) harvested from wild-type CD-1 control (n = 3 each duodenum, jejunum, and ileum), *ROSA26*^*lnlG4*/+^ control (n = 3 ileum), *Gata4* cKI (*ROSA26*^*lnlG4/+*^*Villin-Cre*, n = 3 ileum), and *Gata4* conditional knockout (cKO) (*Gata4*^*loxP/loxP*^*Villin-Cre*, n = 3 jejunum) animals. The standard manufacturer's procedure for GeneChip Mouse Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA) was followed. Arrays were scanned using a 7G Affymetrix GeneChip Scanner (Affymetrix). Data were analyzed using Partek Genomics Suite software version 6.6 (Partek, Inc, St. Louis, MO). A threshold of at least 2.0-fold change with an unadjusted *P* value of .05 or less was used to identify transcripts of interest for all comparisons. To generate gene sets with regionally enriched expression, we performed comparisons between duodenum and jejunum, jejunum and ileum, and duodenum and ileum. By using these 3 comparisons, duodenal-enriched transcripts were defined as those with 2.0-fold (*P* ≤ .05) enrichment over both the jejunum and ileum; jejunal-enriched transcripts were defined as those with 2.0-fold (*P* ≤ .05) enrichment over both duodenum and ileum; and ileal-enriched transcripts were defined as those with 2.0-fold (*P* ≤ .05) enrichment over both duodenum and jejunum. In addition, jejunal/duodenal-enriched transcripts were those with equivalent expression between jejunum and duodenum but with 2.0-fold (*P* ≤ .05) enrichment over ileum. Lists of genes with enriched expression in duodenum, jejunum/duodenum, jejunum, or ileum ([Supplementary Table 1](#mmc1){ref-type="supplementary-material"}) and CEL files from Affymetrix oligonucleotide analysis of ileal epithelium of control and *Gata4* cKI mice were used for Gene Set Enrichment Analysis, and normalized enrichment scores were calculated using default parameters.[@bib37] Microarray data from this study have been deposited into NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo>) and are accessible through GEO series accession number [GSE75870](ncbi-geo:GSE75870){#intref0030}.

Bio-ChIP Sequencing Re-analysis {#sec1.8}
-------------------------------

Previously published and publicly available alignment files for the input and GATA4--bio-ChIP with high-throughput sequencing (GATA4--bio-ChIP-seq) ([GSE68957](ncbi-geo:GSE68957){#intref0035}[@bib38]) were used for peak calling with model-based analysis of ChIP sequencing v1.0 using a *P* value of 10^-5^.[@bib39] The remaining parameters were set to the default. The nearest RefSeq gene for each peak within 100 kb was annotated using CisGenome.[@bib40]

Bio-ChIP {#sec1.9}
--------

Epithelial cell extracts were obtained from the jejunum of *Gata4*^*flbio/flbio*^*::ROSA26*^*BirA/BirA*^ and *ROSA26*^*BirA/BirA*^ (n = 6 per genotype).[@bib30], [@bib31] Cells were fixed in 1% formaldehyde for 10 minutes with rocking followed by 5 minutes quenching in 125 mmol/L glycine. Cell pellets were frozen before sonication using a Misonix Sonicator 3000 (Misonix, Inc, Farmingdale, NY). Bio-ChIP was performed per previously published protocols with modifications described herein.[@bib36], [@bib41] Pull-downs were performed at 4°C using magnetic streptavidin beads (M-280 Dynabeads; Life Technologies) after preclearing chromatin with protein A magnetic beads (Dynabeads). Bead-chromatin complexes were washed for 5 minutes twice with 2% sodium dodecyl sulfate buffer, twice with a high-salt buffer, once with lithium chloride buffer, and twice with Tris-EDTA buffer before chromatin elution in sodium dodecyl sulfate--ChIP elution buffer overnight at 70°C. Eluted chromatin was treated with proteinase K and ribonuclease A followed by phenol-chloroform extraction and ethanol precipitation. GATA4 occupancy was detected by PCR with primers within the GATA4 binding peaks and \[α-^32^P\] dATP. PCR products were separated by 4% polyacrylamide gels in 0.5 × Tris-borate-EDTA buffer and visualized by autoradiography using a Storm820 Phosphor Imager (Amersham Biosciences). Band intensity was measured in ImageQuant 5.2 (Molecular Dynamics, Sunnyvale, CA). Percentage enrichment was calculated by dividing the band intensity for the ChIP sample by 10× the band intensity for the input sample to account for the 1:10 dilution of input sample used in the PCR reaction. A 2-sample Student *t* test was used to compare means.

Electrophoretic mobility Shift Assay {#sec1.10}
------------------------------------

A double-stranded oligonucleotide probe containing an experimentally validated consensus GATA4-binding site from the *Xenopus* *intestinal fatty acid binding protein (xiFABP)* gene[@bib42], [@bib43] was radiolabeled using Klenow fragment and \[α-^32^P\] dATP. Electrophoretic mobility shift assay (EMSA) reactions contained 1× shift buffer (4% Ficoll, 20 mmol/L HEPES pH 7.9, 0.1 mmol/L ethylene glycol-bis(β-aminoethyl ether)-*N,N,N′,N′*-tetraacetic acid, 0.5 mmol/L dithiothreitol), 2 μg nonspecific DNA poly(dIdC), approximately 1 ng of radiolabeled *xiFABP* GATA4 probe, and approximately 1 μg nuclear extract from 293T cells expressing exogenous mouse GATA4 from a plasmid-containing GATA4 (pcDNA-GATA4 plasmid, gift from Stephen Duncan). Each competition EMSA reaction contained a 200-fold molar excess of a specific cold competitor double-strand oligonucleotide probe. Two distinct probes were designed for the *Fgf15* gene because there were 2 consensus GATA4 binding sites within approximately 100 bp of each other within the peak of interest. Each reaction was incubated for 20 minutes at room temperature. A 4% polyacrylamide gel in 0.5 × Tris-borate-EDTA buffer, pre-electrophoresed at 300 V for approximately 2 hours at 4°C, was loaded with 5 µl of the reaction and run at 300 V for 1.5 hours at 4°C. After drying the gel, bands were visualized by autoradiography. Probe sequences are provided in [Table 1](#tbl1){ref-type="table"}.

Results {#sec2}
=======

GATA4 Is Expressed Ectopically in the Ileal Epithelium of ROSA26^lnlGata4/+^Villin-Cre Mice {#sec2.1}
-------------------------------------------------------------------------------------------

We used a conditional knock-in approach to generate mice that ectopically expressed GATA4 in the ileal epithelium ([Figure 1](#fig1){ref-type="fig"}*A*). We targeted the *Gata4* conditional knock-in allele to the *ROSA26* locus because ROSA26 promoter activity is ubiquitous and its disruption results in no adverse phenotype.[@bib32], [@bib44], [@bib45] The targeted allele consisted of the mouse *Gata4* coding sequence downstream of a *loxP* flanked neomyocin resistance gene expression cassette containing a triple polyadenylation (3×pA) signal sequence (LNL cassette). The 3×pA sequence blocks transcriptional read-through to prevent GATA4 expression in the absence of Cre ([Figure 1](#fig1){ref-type="fig"}*A*). GATA4 expression, therefore, was activated by Cre-mediated excision of the LNL cassette ([Figure 1](#fig1){ref-type="fig"}*A*). Southern blot analysis confirmed germline transmission of the conditional knock-in allele (*Gt(ROSA)26Sor*^*tm1(Gata4)Bat*^, designated hereafter as *ROSA26*^*lnlG4*^) ([Figure 1](#fig1){ref-type="fig"}*B*). *ROSA26*^*lnlG4*^ mice were crossed with heterozygous *Villin*-*Cre* mice to activate GATA4 expression within the ileal epithelium. Villin-Cre is expressed in all epithelial cells of the small intestine beginning at E13.5.[@bib22], [@bib28] To verify GATA4 expression in ileum of *ROSA26*^*lnlG4/+*^*Villin-Cre* mice (designated *Gata4* cKI), we analyzed Gata4 messenger RNA (mRNA) levels by qRT-PCR and GATA4 protein levels by immunohistochemistry and immunoblot. Gata4 mRNA was increased significantly in ileum of *Gata4* cKI mice compared with that of controls ([Figure 1](#fig1){ref-type="fig"}*C*). Gata6 transcript levels were equivalent between ileum from control and *Gata4* cKI mice, showing that GATA4 induction in the ileum did not affect Gata6 expression ([Figure 1](#fig1){ref-type="fig"}*C*). Immunohistochemistry staining of ileal tissue sections and immunoblot analysis of ileal epithelial cell nuclear protein fractions showed nuclear GATA4 protein within the ileal epithelium of *Gata4* cKI mice and its absence within nuclei of control ileal epithelial cells ([Figure 1](#fig1){ref-type="fig"}*D* and *E*). GATA4 protein levels also were assessed in jejunal samples from control mice to compare protein levels between normal jejunum and GATA4-expressing ileum. Quantification of immunoblots showed the level of GATA4 in *Gata4* cKI ileum to be approximately 27% of control jejunal level ([Figure 1](#fig1){ref-type="fig"}*E*). In contrast to ileum, we observed no significant increase in GATA4 mRNA or protein in the epithelium of the duodenum or jejunum from *Gata4* cKI mice ([Figure 2](#fig2){ref-type="fig"}). This may reflect the strength of the ROSA26 promoter, or it may indicate that there are post-transcriptional and/or post-translational mechanisms in place in the duodenum and jejunum to regulate the total level of GATA4.

GATA4-Expressing Ileum Loses Ileal Identity {#sec2.2}
-------------------------------------------

To determine the extent to which GATA4 expression in the ileum altered cellular identity, we defined gene sets with regionally enriched expression along the cephalocaudal axis of the normal intestine and compared these sets of regionally enriched transcripts with the gene expression profile of GATA4-expressing ileal epithelium. By using Affymetrix oligonucleotide array analysis, we compared gene expression among epithelial cell populations from the duodenum, jejunum, and ileum. We included duodenal epithelial cells in our analysis to comprehensively characterize regional gene expression along the cephalocaudal intestinal axis. To identify genes with regionally enriched expression in the intestine, we measured differential gene expression between regions (duodenum vs jejunum, jejunum vs ileum, and duodenum vs ileum) using a 2-fold change threshold and an unadjusted *P* value of .05 or less ([Figure 3](#fig3){ref-type="fig"}*A* and [Supplementary Table 1](#mmc1){ref-type="supplementary-material"}). We performed gene set enrichment analysis using jejunal-enriched (130), jejunal/duodenal-enriched (288), duodenal-enriched (846), and ileal-enriched (212) gene sets ([Figure 3](#fig3){ref-type="fig"}*A*) and Affymetrix microarray data profiling gene expression of ileal epithelial cells from *Gata4* cKI and control mice. Gene set enrichment analysis offers an unbiased computational method to determine whether a defined gene set (jejunal-, jejunal/duodenal-, duodenal-, or ileal-enriched gene sets) shows significant enrichment in 1 of 2 biological states (ileal epithelium of *Gata4* cKI vs control mice).[@bib37] We found that the global gene expression profile of *Gata4* cKI ileal epithelium differed significantly from that of control ileal epithelium, aligning more closely with jejunum and duodenum rather than ileum ([Figure 4](#fig4){ref-type="fig"}). We conclude that GATA4-expressing ileum loses ileal identity and that ectopic GATA4 expression within the ileum shifts the ileal transcriptome toward a more proximal identity characteristic of jejunum and duodenum.

Based on the phenotype of GATA4-deficient jejunum, which gained ileal character at the expense of jejunal character,[@bib21] we predicted that transcripts characteristic of proximal intestine (jejunal, jejunal/duodenal, duodenal) would be induced and that transcripts characteristic of distal intestine (ileum) would be reduced in the presence of GATA4 in the ileum. Of the 136 transcripts identified as differentially expressed by at least 2-fold (*P* ≤ .05) between control and GATA4-expressing ileum, 47% (64 of 136) were defined as genes with proximal-enriched (32 transcripts) or distal-enriched (32 transcripts) expression ([Figure 3](#fig3){ref-type="fig"}*A* and [Supplementary Table 2](#mmc2){ref-type="supplementary-material"}). Among these 64 genes, expression of 78% (50 of 64) behaved as predicted, 66% (21 of 32) of the identified jejunal-, jejunal/duodenal-, and duodenal-enriched transcripts increased in ileum of *Gata4* cKI mice compared with controls ([Figure 3](#fig3){ref-type="fig"}*B* an [Table 3](#tbl3){ref-type="table"}), and 91% (29 of 32) of the identified ileal-enriched transcripts decreased in ileum of *Gata4* cKI mice compared with controls ([Figure 3](#fig3){ref-type="fig"}*B* and [Table 3](#tbl3){ref-type="table"}). Within the set of proximal-enriched transcripts up-regulated in GATA4-expressing ileum, 81% (17 of 21) were among the top 25% most duodenal or jejunal-enriched transcripts ([Table 3](#tbl3){ref-type="table"}). Within the set of ileal-enriched transcripts down-regulated in GATA4-expressing ileum, 45% (13 of 29) were among the top 25% most ileal-enriched transcripts ([Table 3](#tbl3){ref-type="table"}). Because the remaining 62 genes identified as differentially expressed between controls and *Gata4* cKI mice were expressed equivalently along the intestinal cephalocaudal axis in wild-type animals, these were not included in subsequent analyses. Of course, it is possible that GATA4 could contribute to regulation of these genes for a purpose other than defining regional specificity.

Our next goal was to identify among these genes those most likely to be regulated directly by GATA4 to establish regional specificity along the cephalocaudal intestinal axis. Because we previously identified a functional defect in jejunum lacking GATA4,[@bib21] we chose to focus the remainder of our analysis on GATA4's regulation of jejunal vs ileal gene expression. Therefore, we focused subsequent analyses on the ileal-enriched genes with repressed expression in GATA4-expressing ileum (29 genes) ([Table 3](#tbl3){ref-type="table"}) and the jejunal-enriched genes with induced expression in GATA4-expressing ileum (17 genes) ([Table 3](#tbl3){ref-type="table"}). For this analysis, jejunal-enriched transcripts were defined as those enriched specifically in the jejunum compared with the duodenum and ileum (8 jejunal-enriched genes) ([Table 3](#tbl3){ref-type="table"}) and those equivalently enriched in both the duodenum and jejunum over the ileum (9 jejunal/duodenal-enriched genes) ([Table 3](#tbl3){ref-type="table"}).

To identify high-confidence GATA4 targets among these 46 genes, we filtered our data further to identify those with converse expression changes in the presence or absence of GATA4 in the jejunum (ie, increased in *Gata4* cKO jejunal epithelium/decreased in *Gata4* cKI ileal epithelium or decreased in *Gata4* cKO jejunal epithelium/increased in *Gata4* cKI ileal epithelium). We determined gene expression changes in jejunal epithelium lacking GATA4 using Affymetrix oligonucleotide array analysis to compare jejunal epithelium of *Gata4* cKO (*Gata4*^*loxP/loxP*^*Villin-Cre*) mice with that of CD-1 control mice ([Figure 3](#fig3){ref-type="fig"}*C* and [Supplementary Table 3](#mmc3){ref-type="supplementary-material"}). Of the 17 jejunal-enriched transcripts up-regulated in *Gata4* cKI ileum, we identified 15 as also down-regulated in the GATA4-null jejunum ([Figure 3](#fig3){ref-type="fig"}*C*). Of the 29 ileal-enriched transcripts down-regulated in *Gata4* cKI ileum, we found 18 as also up-regulated in the GATA4-null jejunum ([Figure 3](#fig3){ref-type="fig"}*C*). In sum, these analyses identified 33 genes as putative high-confidence GATA4 direct targets.

GATA4 Activates and Represses Gene Expression Within the Intestine to Distinguish Jejunal and Ileal Epithelial Regional Identities {#sec2.3}
----------------------------------------------------------------------------------------------------------------------------------

To determine whether GATA4 has the capacity to directly regulate expression of the 33 genes with altered expression in both GATA4-expressing ileum and GATA4-deficient jejunum, we obtained publically available GATA4 bio-ChIP-seq data[@bib38] and identified GATA4 chromatin occupancy using model-based analysis of ChIP-seq for peak calling with a 2-sided and increased *P* value threshold to reduce identification of false-positive peaks.[@bib39] Peaks within 100 kb upstream or downstream of the nearest transcription start site (TSS) were annotated ([Supplementary Table 4](#mmc4){ref-type="supplementary-material"}), and GATA4 binding peaks were identified in 30 of the 33 genes. We subsequently eliminated any genes that failed RT-PCR validation for differential expression between ileum of *Gata4* cKI and control or between jejunum of *Gata4* cKO and control ([Figure 5](#fig5){ref-type="fig"}), reducing the set to 26 potential high-confidence GATA4-regulated targets ([Table 4](#tbl4){ref-type="table"}). We performed bio-ChIP--PCR using sonicated chromatin from isolated jejunal epithelial cells of *Gata4*^*flbio/flbio*^*::ROSA26*^*BirA/BirA*^ mice and *ROSA26*^*BirA/BirA*^ mice[@bib30], [@bib31], [@bib41] ([Figure 6](#fig6){ref-type="fig"}). Biotinylation of endogenous GATA4 protein in *Gata4*^*flbio/flbio*^*::ROSA26*^*BirA/BirA*^ mice allows precipitation of GATA4-chromatin complexes with streptavidin.[@bib30], [@bib31], [@bib41] We performed 3 independent streptavidin pull-downs, each including chromatin harvested from 2 *Gata4*^*flbio/flbio*^*::ROSA26*^*BirA/BirA*^ animals and 2 *ROSA26*^*BirA/BirA*^ animals (n = 6 animals of each genotype assayed by bio-ChIP--PCR). We identified the GATA4 binding peak closest to each gene's TSS and verified that each contained at least 1 consensus GATA4 binding site (A/T-GATA-A/G). Primers flanking the tallest point of the bio-ChIP-seq peak were used for PCR. For negative controls, we designed primers to assay GATA4 occupancy at regions in intestinal-expressed genes that lack GATA4 bio-ChIP-seq peaks (*Dll1, Hprt, Prss23, Slc10a2,* and *Ugt2a3*) and to assay GATA4 occupancy at sequences in genes identified as GATA4 targets in other tissues but that are either equivalently expressed in ileum of control and *Gata4* cKI mice (*Cdk4*)[@bib46] or absent in ileum of control and *Gata4* cKI mice (*Alb*).[@bib47], [@bib48] GATA4 enrichment at putative binding sites in jejunal chromatin from *Gata4*^*flbio/flbio*^*::ROSA26*^*BirA/BirA*^ animals compared with that of controls was measured and expressed as a percentage of input ([Figure 6](#fig6){ref-type="fig"}, [Figure 7](#fig7){ref-type="fig"} shows representative PCR autoradiographs for each site assayed). We observed GATA4 binding at 9 of 12 regions identified as encoding jejunal-enriched transcripts up-regulated in GATA4-expressing ileum and at 13 of 14 regions identified within genes encoding ileal-enriched transcripts down-regulated in GATA4-expressing ileum ([Figure 6](#fig6){ref-type="fig"}). For the 4 genes lacking statistically significant GATA4 enrichment at the peaks residing closest to the gene's TSS, we examined GATA4 bio-ChIP-seq data to identify the next GATA4 binding peak containing at least 1 consensus GATA binding site. We identified such peaks in 2 of the 4 genes (*Slc10a2*, peak ∼68 kb downstream of TSS within an intron; *Asah2*, peak ∼26 kb upstream of the TSS) and assayed GATA4 occupancy at these regions by bio-ChIP-PCR. We observed GATA4 binding to both regions ([Figure 6](#fig6){ref-type="fig"}). Taken together, we found that GATA4 binds to sites in all genes identified as encoding ileal-enriched transcripts down-regulated in GATA4-expressing ileum and that GATA4 binds to sites in 10 of 12 genes (83%) identified as encoding jejunal-enriched transcripts up-regulated by expression of GATA4 in the ileum ([Figure 7](#fig7){ref-type="fig"}). As expected, GATA4 was not enriched at any negative control sequence queried (0 of 7) ([Figure 6](#fig6){ref-type="fig"}).

As proof in principle that our methodology identified bona fide GATA4 binding sequences, we selected 2 genes with jejunal-enriched expression (*Lct* and *Cd36*) and 2 with ileal-enriched (*Fgf15* and *Slc10a2*) expression and used an EMSA to test GATA4 binding to its binding sites within these genes ([Figure 8](#fig8){ref-type="fig"}). Nonradiolabeled probes containing gene-specific GATA4 consensus sequence(s) previously queried by bio-ChIP-PCR ([Figure 8](#fig8){ref-type="fig"}*A*) were tested for their ability to compete with a well-characterized GATA4 binding site from the *Xenopus* *intestinal fatty acid binding protein (xiFABP)* gene[@bib42], [@bib43] for binding to exogenous GATA4 protein ([Figure 8](#fig8){ref-type="fig"}*B*). We also introduced mutations into each GATA4 consensus sequence ([Figure 8](#fig8){ref-type="fig"}*A*) and tested the ability of each mutant to compete for GATA4 binding by EMSA. The unlabeled xiFABP sequence as well as every unlabeled wild-type GATA4 consensus binding site from the targets tested inhibited GATA4 binding to the radiolabeled xiFABP probe ([Figure 8](#fig8){ref-type="fig"}*C*). In contrast, all mutated GATA4 consensus sequences failed to compete with or minimally competed with the radiolabeled xiFABP probe for GATA4 binding ([Figure 8](#fig8){ref-type="fig"}*C*). Taken together, GATA4 binding data (EMSA and ChIP) and our observation of converse changes in gene expression in ileum expressing GATA4 and jejunum lacking GATA4 strongly suggest that GATA4 regulates regional gene expression within the intestine by directly binding to genes encoding jejunal transcripts to activate transcription and to genes encoding ileal transcripts to repress transcription. Of course, to definitively prove direct regulation of these genes by GATA4, it would be necessary to mutate the GATA4 binding sites within these targets and show that such mutations abolish GATA4-dependent regulation of target gene expression within mouse jejunal epithelium.

Expression of GATA4 Jejunal Targets Is Not Increased in Jejunum of Gata4 cKI Mice {#sec2.4}
---------------------------------------------------------------------------------

We compared the expression of the 10 jejunal-enriched targets occupied by GATA4 in jejunal epithelium from control and *Gata4* cKI mice by qRT-PCR. We found only Fabp1 transcript to be increased significantly between these groups ([Figure 9](#fig9){ref-type="fig"}*A*). Although interleukin 33 (Il33) transcript was increased, the *P* value for this change was just outside the significance cut-off value of *P* \< .05. We also used qRT-PCR to compare expression of 4 transcripts identified by our analysis as duodenal-enriched (Akr1b8, Cck, Pdx1, and Sst) ([Supplementary Table 1](#mmc1){ref-type="supplementary-material"}) in duodenal epithelium from control and *Gata4* cKI mice. We observed no difference in these markers between control and *Gata4* cKI mice ([Figure 9](#fig9){ref-type="fig"}*B*). Although Cck and Sst transcript levels trended toward slightly higher levels in the duodenum of *Gata4* cKI mice compared with controls, the *P* value for these was outside of the significance cut-off value of *P* \< .05. These results were not unexpected because we showed earlier that GATA4 protein was not increased significantly in the duodenum or jejunum of *Gata4* cKI mice compared with controls ([Figure 2](#fig2){ref-type="fig"}).

Enterohepatic Circulation Is Altered in Gata4 cKI Mice {#sec2.5}
------------------------------------------------------

Among the set of GATA4 targets repressed in GATA4-expressing ileum were those involved in regulating an important enterohepatic circulation pathway. Uptake of luminal bile acids by ileal enterocytes occurs via the bile acid transporter SLC10A2.[@bib49] Within enterocytes, bile acids bind to the intracellular bile acid binding protein FABP6 and ultimately are transported from the enterocyte into the circulation by the basolateral heterodimeric organic solute transporter (OST), which consists of OSTα and OSTβ proteins (encoded by the *Slc51a* and *Slc51b* genes, respectively).[@bib6], [@bib50] Bile acids also act as ligands for the nuclear receptor FXR.[@bib6] Bile acid--bound FXR promotes *Fgf15* expression, and secretion of FGF15 into the portal venous circulation results in FGF receptor 4 activation on hepatocytes.[@bib4], [@bib5] This activation inhibits expression of *Cyp7a1*, the gene encoding the rate-limiting enzyme in bile acid synthesis.[@bib4] Genes encoding proteins involved in this pathway that were decreased significantly in GATA4-expressing ileum included *Slc10a2*, *Fabp6*, and *Fgf15* ([Table 3](#tbl3){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}). Moreover, by relaxing the fold-change criterion in analyzing transcripts altered in GATA4-expressing ileum, we found expression of 3 additional transcripts encoding ileal-enriched bile acid uptake pathway proteins to be decreased: Nr1h4 (Fxr), -1.4-fold, *P* ≤ .05; Slc51a (Ostα), -1.7-fold, *P* ≤ .01; and Slc51b (Ostβ), -1.6-fold, *P* ≤ .05. To determine if changes in mRNA abundance correlated with changes in protein abundance, we performed immunohistochemistry to compare SLC10A2 levels in ileum between *Gata4* cKI mice and control mice. Overall, we observed decreased SLC10A2 protein at the epithelial brush border of ileum from *Gata4* cKI mice compared with control mice (n = 7 control, n = 14 *Gata4* cKI) ([Figure 10](#fig10){ref-type="fig"}*A*). In some regions, SLC10A2 was undetectable ([Figure 10](#fig10){ref-type="fig"}*A*, bottom panel); in other regions, SLC10A2 levels were greatly reduced ([Figure 10](#fig10){ref-type="fig"}*A*, middle panel). We used immunoblot to quantify total SLC10A2, OSTα, and OSTβ proteins in GATA4-expressing ileal enterocytes and control ileal enterocytes and found that ileum of *Gata4* cKI mice contained only 9% of SLC10A2 protein typical of control tissue ([Figure 10](#fig10){ref-type="fig"}*B*) and only 26% and 19% of OSTα and OSTβ proteins typical of control tissue, respectively ([Figure 10](#fig10){ref-type="fig"}*C*). Because we observed lower levels of transcripts and proteins encoded by genes required for bile acid uptake and enterohepatic signaling, we examined the expression of hepatic *Cyp7a1*. We found Cyp7a1 mRNA expression to be increased significantly in livers of *Gata4* cKI mice compared with that of controls ([Figure 10](#fig10){ref-type="fig"}*D*). These findings are consistent with decreased Cyp7a1 transcript observed in livers of *Gata4* cKO animals.[@bib21] Therefore, we conclude that enterohepatic signaling was altered in mice expressing GATA4 in the ileum.

Lactase Protein Is Induced in the Ileum of Gata4 cKI Mice {#sec2.6}
---------------------------------------------------------

The finding that changes in ileal-specific gene transcription affected ileal-specific protein expression led us to examine the status of jejunal protein expression in GATA4-expressing ileum. Because lactase (LCT), a well-documented marker of jejunal function, was identified as the top jejunal target induced by expression of GATA4 in the ileum ([Table 3](#tbl3){ref-type="table"}), we chose to examine LCT protein expression in ileum of control and *Gata4* cKI mice. We used immunostaining and immunoblot analyses to examine LCT protein expression in ileum from control and *Gata4* cKI mice. We observed brush-border expression of LCT protein only in GATA4-expressing ileum ([Figure 11](#fig11){ref-type="fig"}*A*). Immunoblot analysis further showed induction of LCT protein in ileal epithelial cells of *Gata4* cKI mice and not in cells of control mice ([Figure 11](#fig11){ref-type="fig"}*B*). These data show that GATA4-expressing ileal cells can express jejunal proteins and suggest that these cells would be capable of accomplishing jejunal functions.

Discussion {#sec3}
==========

Together, our data show that GATA4 is sufficient to confer jejunal identity and to repress ileal identity in the small intestinal epithelium. These findings refine our understanding of GATA4's critical function in patterning the intestinal epithelium along its cephalocaudal axis, initially uncovered through studies with *Gata4* cKO mice.[@bib19], [@bib21], [@bib24] Moreover, we identified a novel mechanism through which GATA4 may directly repress *Fgf15* expression to influence enterohepatic signaling. Although the level of GATA4 protein expressed in *Gata4* cKI ileal epithelium was only 27% of that expressed in jejunal epithelium, it nevertheless was sufficient to alter the global ileal gene expression profile such that it aligned more closely with jejunum and duodenum rather than ileum. Of the genes with expression changed by addition of GATA4 to the ileum, roughly half were genes with proximal-enriched (jejunal and duodenal) or ileal-enriched expression patterns. Moreover, gene expression not only was affected positively by the presence of GATA4 but also was affected negatively, implying that GATA4 normally patterns the jejunal-ileal boundary by activating and repressing transcription.

Our approach to identify and to validate GATA4 transcriptional targets among those genes encoding jejunal-enriched or ileal-enriched transcripts was stringent. The facts that we confirmed GATA4 occupancy by ChIP in all but 2 of the 26 genes (92%) we identified and that we showed GATA4 binding to its consensus sites within a subset of these genes by EMSA show the validity of our approach to identify GATA4 targets involved in regulating jejunal vs ileal identity. Because we limited our analysis of GATA4 binding sites to those satisfying specific and stringent criteria, we cannot exclude the possibility that additional important GATA4 targets involved in determining jejunal vs ileal identity exist and were omitted by our analysis. The number of genes encoding jejunal- or ileal-enriched transcripts regulated by GATA4 to define the jejunal-ileal boundary, therefore, likely was under-represented by this analysis. Nevertheless, we conclude that GATA4 patterns the intestinal jejunal-ileal boundary by activating and repressing transcription of key regional-defining transcripts within the jejunum.

An important consequence of patterning discrete jejunal and ileal domains is the restriction of bile acid absorption to the ileum. We conclude that GATA4 controls spatial patterning of bile acid absorption along the cephalocaudal axis of the small intestine by repressing expression of key genes encoding proteins essential for bile acid homeostasis. Our work supports a model in which GATA4 prevents inappropriate proximal absorption of bile acids by directly suppressing *Slc10a2*, *Fabp6*, and *Fgf15* expression; exclusion of GATA4 from the terminal ileum thereby provides a permissive environment for transcription of these same genes and, therefore, for bile acid uptake. Moreover, GATA4 may directly repress additional genes encoding important regulators of bile acid homeostasis that were not identified by our study. Our strategy required 2-fold changes in gene expression in both GATA4-deficient jejunum and GATA4-expressing ileum. The level of GATA4 reconstituted in mutant ileum, however, was not equivalent to that normally expressed in jejunum. Therefore, it is possible that the amount of GATA4 present in ileum of *Gata4* cKI mice was insufficient to reduce expression of some targets by the 2-fold threshold. In fact, by relaxing the fold-change criterion in analyzing transcripts altered in GATA4-expressing ileum, we identified 3 additional key bile acid pathway genes---*Nr1h4*, *Slc51a*, and *Slc51b*--- with decreased expression in GATA4-expressing ileum. Moreover, expression of *Nr1h4*, *Slc51a*, and *Slc51b* was increased in GATA4-deficient jejunum ([Supplementary Table 3](#mmc3){ref-type="supplementary-material"} and Battle et al[@bib21]), and each contains GATA4 binding peaks ([Supplementary Table 4](#mmc4){ref-type="supplementary-material"}), suggesting these genes as additional possible direct GATA4 targets. These data suggest that GATA4 coordinates the repression of expression of multiple genes required for bile acid absorption, thereby excluding this function from the jejunum, which is important for efficient lipid uptake by the jejunum.

By contributing to spatial regulation of bile acid homeostasis, GATA4 influences FGF15-mediated enterohepatic signaling. FGF15 functions as a hormone with a primary target being the liver where it controls hepatic expression of *Cyp7a1*, the gene encoding the rate-limiting enzyme for synthesis of bile acids from cholesterol.[@bib3], [@bib4], [@bib6], [@bib51], [@bib52], [@bib53] Supporting a role for GATA4 in modulating FGF15-mediated enterohepatic signaling, we found that hepatic Cyp7a1 levels were increased 4-fold in *Gata4* cKI mice, which express little to no intestinal Fgf15. This agrees with our previous finding that *Gata4* intestinal cKO mice, which overexpress Fgf15 in the jejunum, have decreased hepatic Cyp7a1 transcript.[@bib21] GATA4 likely influences Fgf15 levels through direct and indirect mechanisms. GATA4 repression of *Slc10a2* expression would suppress cellular bile acid uptake and downstream bile acid activation of FXR-mediated *Fgf15* transcription.[@bib4], [@bib5], [@bib52], [@bib53] Moreover, as described earlier, GATA4 also may repress transcription of *Fxr* itself, and in this way could reinforce silencing of *Fgf15* and other FXR transcriptional targets such as *Fabp6*, *Slc51a*, and *Slc51b* in the jejunum.[@bib50], [@bib54] Importantly, we show that GATA4 likely directly represses *Fgf15* expression by binding to a consensus GATA4 regulatory element in intron 2 of the *Fgf15* gene. These sites are approximately 140-bp upstream of a consensus FXR binding site shown to be important for *Fgf15* expression.[@bib4] The proximity of GATA4 and FXR binding sites within the *Fgf15* gene suggests that GATA4 potentially could modulate FXR binding to *Fgf15*. Because defects in enterohepatic FGF15/19 signaling have been linked to human diseases including cholestatic liver disease, nonalcoholic fatty liver disease, type 2 diabetes, metabolic syndrome, Crohn's disease, bile acid malabsorption, and bile acid diarrhea,[@bib7], [@bib8], [@bib9], [@bib11] it is important to understand how *Fgf15* is regulated, and our study contributes a novel mechanism through which GATA4 represses *Fgf15* transcription within the proximal intestine to maintain appropriate FGF15 levels.

Our finding that lactase protein was expressed in the brush border of ileal enterocytes in *Gata4* cKI mice implies that in addition to changing the ileal transcriptome, GATA4 expression in the ileum has the capacity to confer jejunal function to the ileum. Directly showing enhanced jejunal function in *Gata4* cKI mice, however, would be virtually impossible given that the endogenous jejunal domain is fully intact and fully functional in *Gata4* cKI mice. The jejunum is very efficient in performing its digestive and absorptive tasks. For example, we previously have shown that wild-type mice absorb approximately 97% of dietary fat.[@bib21] Given the saturated level of jejunal function in mice with an intact jejunum, it would be quite difficult to experimentally detect an enhancement of jejunal function. It is likely that detection of a measurable enhancement of jejunal function in the ileum of *Gata4* cKI mice would require disruption of endogenous jejunal function, which is beyond the scope of this study.

In summary, we show that GATA4 is sufficient to establish jejunal enterocyte identity and to repress ileal enterocyte identity in the intestinal epithelium. Not only are key jejunal- and ileal-enriched transcript levels changed in GATA4-expressing ileum, but levels of jejunal- and ileal-enriched proteins also are altered in GATA4-expressing ileum. Changes in liver gene expression in *Gata4* cKI mice, downstream of bile acid and FGF15 signaling, show that there are important physiological consequences resulting from the addition of GATA4 to the ileum. This study hones our understanding of a key GATA4-dependent molecular mechanism that patterns the intestinal epithelium along its cephalocaudal axis by elaborating on GATA4's critical function as an essential dominant molecular determinant of jejunal enterocyte identity. Future studies to determine how GATA4 discriminates between targets that it activates or represses will be important. Genetic evidence suggests that FOG1 is essential for GATA4-mediated repression of at least *Slc10a2* and *Fabp6*.[@bib24] GATA4-dependent inhibition of histone H3 lysine 27 acetylation also has been implicated as a mechanism through which GATA4 represses transcription.[@bib38] Finally, as a factor that is both necessary and sufficient to program jejunal enterocyte identity, GATA4 represents a logical candidate to consider in developing therapies to treat intestinal failure, particularly for those designed to restore lost functions to remaining intestinal tissue or for tissue-engineering approaches to overcome small-bowel organ shortages for transplant.
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![***Gata4* conditional knock-in mice express GATA4 in the ileum.** (*A*) Schematic illustrating the strategy used to generate a conditional *Gata4* knock-in mouse line. The coding sequence of the mouse *Gata4* gene was amplified by PCR and inserted into *XhoI/SacI* sites in the multiple cloning site (MCS) of pBig-T to generate pBigT-*Gata4*. The targeting cassette consisting of an adenoviral splice acceptor (SA), a *loxP* flanked phosphoglycerate kinase (PGK) promoter-neomycin resistance gene (Neo) and 3×SV40 polyadenylation sequence (pA) sequence (*loxP*-PGK-Neo-3×SV40pA-*loxP*, LNL), the *Gata4* coding sequence, and a bovine growth hormone polyadenylation (pA) sequence was excised from pBigT-*Gata4* with *PacI/AscI* and inserted into the *PacI/AscI* sites in pROSA26PA to create pROSA26PA-*Gata4*. Homologous recombination between pROSA26PA-*Gata4* and the endogenous *ROSA26* locus in mouse R1 embryonic stem cells yielded the targeted locus *Gt(ROSA)26Sor*^*tm1(Gata4)Bat*^, designated *ROSA26*^*lnlG4*^. After Cre recombination to excise the LNL cassette, Gata4 is expressed. *BamHI* (*B*) and *EcoRV* (*E*) restriction sites used for Southern blot analysis, the position of Southern blot probes, and relevant *BamHI* and *EcoRV* restriction digest fragments identified by Southern blot are shown. *Arrows* mark sites of genotyping primers ([Table 1](#tbl1){ref-type="table"}, primers). (*B*) Southern blot analysis confirmed germline transmission of the *ROSA26*^*lnlG4*^ allele. Representative Southern blot analysis of *EcoRV* or *BamHI* digested genomic DNA harvested from a wild-type mouse (ROSA26^+/+^) or a mouse heterozygous for the modified ROSA26 allele (*ROSA26*^*lnlG4/+*^). We observed the expected fragments representing the wild-type and modified alleles (*EcoRV* digest, 11.5-kb wild-type allele and 4.0-kb modified allele; *BamHI* digest, 5.8-kb wild-type allele and 4.7-kb modified allele). (*C*) qRT-PCR showed that Gata4 mRNA was induced in ileum of *ROSA26*^*lnlG4/+*^*Villin-Cre* (designated *Gata4* cKI) mice compared with ileum of control mice (*ROSA26*^*lnlG4/+*^). Gata6 mRNA remained unchanged in the ileum of *Gata4* cKI mice compared with controls (n = ileum of 5 control and 6 *Gata4* cKI animals; experiments performed in triplicate). Glyceraldehyde-3-phosphate dehydrogenase was used for normalization. Error bars show SEM. *P* values were determined by 2-sample Student *t* test: \**P* ≤ .05. (*D*) Immunohistochemistry showed nuclear GATA4 protein (brown staining) in ileal epithelium of *Gata4* cKI mice and in the jejunal epithelium of control mice whereas GATA4 protein was absent from ileal epithelium of control mice. Sections from at least 3 control and 3 *Gata4* cKI animals were evaluated. Hematoxylin was used to counterstain tissue. *Scale bars*: 100 μm. (*E*) Immunoblot analysis of nuclear extracts from jejunal and ileal epithelial cells of control mice and from ileal epithelial cells of *Gata4* cKI mice was used to quantify GATA4 protein in ileum of *Gata4* cKI mice and to compare GATA4 abundance between control jejunum and GATA4-expressing ileum. The blot shown contains nuclear protein extracts from 3 control and 3 *Gata4* cKI animals and is representative of analysis of more than 24 control and *Gata4* cKI animals. To quantify protein expression, signal was measured using quantitative infrared immunoblotting (LI-COR) and National Institutes of Health ImageJ software. GATA4 protein levels were normalized to TATA binding protein (TBP) levels. GATA4 expression in ileum of *Gata4* cKI mice was 27% the level observed in control jejunum. Molecular weight marker locations are indicated. Error bars show SEM. *P* values determined by 2-sample Student *t* test: \**P* ≤ .05, \*\**P* ≤ .001.](gr1){#fig1}

![**Duodenal and jejunal epithelial cells in *Gata4* cKI mice express normal levels of GATA4.** (*A*) Immunohistochemistry showed nuclear GATA4 protein (brown staining) in duodenal and jejunal epithelium of *Gata4* cKI mice at similar staining intensity compared with controls. Sections from at least 3 control and 3 *Gata4* cKI animals were evaluated. Hematoxylin was used to counterstain tissue. *Scale bars*: 100 μm. (*B*) qRT-PCR showed that Gata4 mRNA was unchanged in epithelial cells of the duodenum and jejunum of *ROSA26*^*lnlG4/+*^*Villin-Cre* (designated *Gata4* cKI) mice compared with control mice (*ROSA26*^*lnlG4/+*^) (n = 3 per genotype; experiments performed in triplicate). Glyceraldehyde-3-phosphate dehydrogenase was used for normalization. Error bars show SEM. *P* values were determined by 2-sample Student *t* test. (*C*) Immunoblot analysis of nuclear extracts from duodenal and jejunal epithelial cells of control and *Gata4* cKI mice was used to quantify GATA4 protein (n = 3 per genotype). To quantify protein expression, signal was measured using quantitative infrared immunoblotting (LI-COR) and National Institutes of Health ImageJ software. GATA4 protein levels were normalized to TATA binding protein (TBP) levels. GATA4 expression was unchanged in duodenum and jejunum of *Gata4* cKI animals compared with control. Molecular weight marker locations are indicated. Error bars show SEM. *P* values were determined by 2-sample Student *t* test.](gr2){#fig2}

![**Identification of high-confidence GATA4 targets that define jejunal vs ileal enterocyte identity.** (*A*) We used Affymetrix oligonucleotide array analysis with RNA from wild-type (WT) CD-1 duodenal, jejunal, and ileal epithelial cells (n = 3) to identify sets of regionally enriched transcripts and with RNA from ileal epithelial cells of control (*Rosa26*^*lnlG4/+*^) and *Gata4* cKI (*Rosa26*^*lnlG4/+*^*Villin-Cre*) mice (n = 3 per genotype) to identify transcripts altered in GATA4-expressing (GATA+) ileum compared with control ileum. A threshold of at least a 2-fold change and an unadjusted *P* value ≤ .05 was used for comparisons. We determined overlap between transcripts differentially expressed in GATA4+ ileum (136 transcripts) and those identified as either duodenal-enriched, jejunal/duodenal-enriched, jejunal-enriched, or ileal-enriched (*bolded text*). We found that 47% of transcripts with altered expression in GATA4+ ileum overlapped with proximal-enriched (duodenal, jejunal/duodenal, and jejunal sets, indicated by *bracket*) or ileal-enriched transcript sets (64 of 136, 32 proximal-enriched, 32 ileal-enriched). (*B*) Of the 32 proximal-enriched transcripts identified, the expression of 21 was increased in GATA4+ ileum. Of the 32 ileal-enriched transcripts identified, the expression of 29 was decreased in GATA4+ ileum. (*C*) Focusing on the jejunal-enriched set (17 transcripts, including 15 jejunal-enriched and 12 jejunal/duodenal-enriched) and the ileal-enriched set (29 transcripts), we reasoned that high-confidence GATA4 direct targets would show converse expression changes in the presence or absence of GATA. Therefore, to identify transcripts differentially expressed in GATA4-deficient jejunum, we used Affymetrix oligonucleotide array analysis with RNA from jejunal epithelial cells of *Gata4* cKO (*Gata4*^*loxP/loxP*^*Villin-Cre*) mice (n = 3) and WT CD-1 mice (n = 3, same arrays as in panel *A*). A threshold of at least a 2-fold change and an unadjusted *P* value ≤ .05 was used. We determined overlap between the 46 jejunal- or ileal-enriched transcripts and those transcripts differentially expressed in GATA4-deficient jejunum (466 transcripts). We found that 15 of 17 jejunal-enriched transcripts with increased expression in GATA4+ ileum and 18 of 29 ileal-enriched transcripts with decreased expression in GATA4+ ileum overlapped with those altered in GATA4-deficient jejunum and that all 33 overlapping transcripts showed a converse expression pattern in GATA4-deficient jejunum compared with GATA4+ ileum (ie, expression of all 15 jejunal-enriched transcripts was decreased in GATA4-deficient jejunum and expression of all 18 ileal-enriched transcripts was increased in GATA4-deficient jejunum). Specific jejunal- and ileal-enriched transcripts are listed in the *box*. Those *bolded* are important in the enterohepatic circulation pathway.](gr3){#fig3}

![**GATA4-expressing ileum loses ileal identity.** Transcripts identified as having enriched expression in the epithelium of duodenum, jejunum/duodenum, jejunum, or ileum of wild-type animals ([Figure 3](#fig3){ref-type="fig"}*A* and [Supplementary Table 1](#mmc1){ref-type="supplementary-material"}) were used as reference gene sets in gene set enrichment analysis. CEL files for microarrays performed with RNA isolated from ileal epithelial cells of control (*Rosa26*^*lnlG4/+*^) and *Gata4* cKI (*Rosa26*^*lnlG4/+*^*Villin-Cre*) mice (n = 3 per genotype) were tested for enrichment of gene sets by gene set enrichment analysis. The *top panels* and *bottom left panel* show gene set enrichment analysis using transcripts enriched in duodenal (*top left*), jejunal/duodenal (*top right*), or jejunal (*bottom left*) epithelium as the reference gene set; the *bottom left panel* shows gene set enrichment analysis using transcripts enriched in ileal epithelium as the reference gene set. Proximal transcripts were highly enriched (normalized enrichment score \[NES\] = +2.27, +2.84, and +1.92) in GATA4-expressing (GATA4+) ileum, whereas ileal transcripts were enriched in control ileum (NES = -3.63). All were statistically significant by *P* value and false-discovery rate (FDR).](gr4){#fig4}

![**Validation of converse gene expression patterns for jejunal- or ileal-enriched transcripts in GATA4-expressing (GATA4+) ileum and GATA4-deficient (GATA4-) jejunum.** RT-PCR was used to determine transcript abundance for the 30 jejunal- and ileal-enriched transcripts, identified as having GATA4 binding peaks by bio-ChIP-seq, in ileal epithelial cells from *Gata4* cKI (*ROSA26*^*lnlG4/+*^*Villin-Cre*) and control (*ROSA26*^*lnlG4/+*^) mice and in jejunal epithelial cells from *Gata4* cKO (*Gata4*^*loxP/loxP*^*Villin-Cre*) and control (WT CD-1) mice. The 26 genes confirmed to have converse gene expression patterns in GATA4+ ileum and GATA4- jejunum are shown in *bold*. Glyceraldehyde-3-phosphate dehydrogenase was used for normalization. Expression of each gene was assayed in at least 3 independent experiments using cDNA from n = 3--6 for control, *Gata4* cKI, and *Gata4* cKO animals. Error bars represent SEM. \**P* ≤ .05. \*\**P* ≤ .01.](gr5){#fig5}

![**GATA4 occupies sites in jejunal- and ileal-enriched genes, suggesting GATA4 directly regulates expression of jejunal- and ileal-enriched genes in the jejunum to define jejunal enterocyte identity.** Bio-ChIP--PCR showed GATA4 enrichment at GATA4 binding sites within genes expressed in jejunum (*top panel*) and within genes repressed in jejunum (*middle panel*). No GATA4 enrichment was observed at sites lacking GATA4 bio-ChIP-seq binding sites (*Dll1, Hprt, Prss23, Slc10a2,* and *Ugt2a3*) or in genes identified as GATA4 targets in other tissues but that are either equivalently expressed in ileum of control and *Gata4* cKI mice (*Cdk4*) or absent in ileum of control and *Gata4* cKI mice (*Alb*) (*bottom panel*). Audioradiographic band intensity was measured using a Storm820 Phosphor Imager and ImageQuant software. Representative autoradiographs for each site assayed are shown in [Figure 7](#fig7){ref-type="fig"}. Enrichment per sample was normalized to input (n = 6 *Gata4*^*flbio/flbio*^*::ROSA26*^*BirA/BirA*^ mice, designated *GATA4-FlagBio/BirA*, and 6 *ROSA26*^*BirA/BirA*^ mice, designated *GATA4-WT/BirA*). Error bars show SEM. *P* values were determined by 2-sample Student *t* test: \**P* ≤ .05, \*\**P* ≤ .005. *P* values \> .05 are listed on graphs. GATA4 occupancy at the binding sites in the *Slc10a2* gene (*Slc10a2*\_1 and *Slc10a2*\_2) was analyzed previously by qPCR.[@bib38]](gr6){#fig6}

![**Representative autoradiographs of bio-ChIP--PCR.** Bio-ChIP--PCR was used to evaluate GATA4 occupancy at predicted binding sites in the 26 high-confidence direct targets we identified and in 7 negative controls (*Alb, Cdk4, Dll1, Hprt, Prss23, Slc10a2,* and *Ugt2a3*). GATA4 occupied chromatin was isolated by performing streptavidin pull-down with chromatin from jejunal epithelial cells of *GATA4-FlagBio/BirA* or *GATA4-WT/BirA* mice. As representative data, PCR with chromatin from 2 mice per genotype is shown here. Input PCR confirmed that equivalent chromatin amounts were used in pull-downs. In all, 6 mice per genotype were assayed by bio-ChIP--PCR.](gr7){#fig7}

![**GATA4 binds to GATA consensus binding sites in jejunal-enriched genes and in ileal-enriched genes regulated by GATA4 expression in the intestine.** (*A*) Table shows double-stranded oligonucleotide EMSA probes (5' to 3'). *Underlined sequences* identify the location of GATA4 consensus binding sites within probes. Nucleotides mutated to eliminate GATA4 consensus binding sites in mutant probes are indicated. Two distinct probes were designed for the *Fgf15* gene because there were 2 consensus GATA4 binding sites within approximately 100 bp of each other within the peak of interest. (*B*) Immunoblot analysis of nuclear extracts from 293T cells transfected with either control empty plasmid or GATA4 containing plasmid (pcDNA-GATA4) shows overexpression of GATA4 in pcDNA-GATA4--transfected cells. GATA4 protein levels were normalized to TATA binding protein (TBP) levels. Molecular weight marker locations are indicated. (*C*) Representative EMSA competition assay is shown. Nuclear extract from pcDNA-GATA4--transfected 293T cells was incubated with radiolabeled xiFABP probe in the absence (lane 1) or presence (lanes 2--11) of 200-fold molar excess of unlabeled competitors. A *bracket* indicates the location of GATA4-bound xiFABP probe. Data are representative of 3 independent assays.](gr8){#fig8}

![**Expression of jejunal and duodenal transcripts is unchanged in *Gata4* cKI animals.** (*A*) qRT-PCR was used to determine transcript abundance of the 10 jejunal-enriched transcripts, identified as having enriched GATA4 binding by bio-ChIP--PCR ([Figure 7](#fig7){ref-type="fig"}) in jejunal epithelial cells from control and *Gata4* cKI mice. (*B*) qRT-PCR was used to determine transcript abundance of 4 duodenal transcripts in duodenal epithelial cells from control and *Gata4* cKI mice. (*A* and *B*) Glyceraldehyde-3-phosphate dehydrogenase was used for normalization. Expression of each gene was assayed in at least 3 independent experiments (n = 3 per genotype). Error bars represent SEM. *P* values were determined by 2-sample Student *t* test.](gr9){#fig9}

![**Enterohepatic signaling is altered in animals expressing GATA4 in the ileum.** (*A*) Immunohistochemistry for SLC10A2 (brown stain) shows SLC10A2 protein lining the brush border of control ileum (n = 7, upper panel). In contrast, SLC10A2 staining was faint to nearly absent along the brush border of ileum from *Gata4* cKI mice (n = 14, 7 of 14 faint SLC10A2 staining, *middle panel*, and 7 of 14 low to no SLC10A2 staining, *lower panel*). Immunohistochemistry from 2 independent *Gata4* cKI mice is shown as representative of the 2 types of SLC10A2 staining observed. (*B*) Immunoblot using whole-cell extracts from ileal epithelium of control and *Gata4* cKI mice was used to measure expression of SLC10A2 protein. To quantify protein expression, signal was measured using quantitative infrared immunoblotting (LI-COR) and National Institutes of Health ImageJ software. SLC10A2 protein levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. SLC10A2 expression in ileum of *Gata4* cKI mice (*ROSA26*^*lnlG4/+*^*Villin-Cre*) was 9% of the level observed in control ileum (*ROSA26*^*lnlG4/+*^; n = 3 animals per genotype). *Arrowhead* indicates the SLC10A2 band measured. Molecular weight marker locations are indicated. Error bars show SEM. *P* values were determined by 2-sample Student *t* test: \**P* ≤ .05. (*C*) Immunoblot using whole-cell extracts from ileal epithelium of control and *Gata4* cKI mice was used to measure expression of OSTα and OSTβ proteins. To quantify protein expression, signal was measured using quantitative infrared immunoblotting (LI-COR) and National Institutes of Health ImageJ software. OSTα and OSTβ protein levels were normalized to GAPDH levels. Expression of OSTα and OSTβ proteins in ileum of *Gata4* cKI mice (*ROSA26*^*lnlG4/+*^*Villin-Cre*) was 26% and 19% of the level observed in control ileum (*ROSA26*^*lnlG4/+*^), respectively (n = 3 animals per genotype). Molecular weight marker locations are indicated. Error bars show SEM. *P* values were determined by 2-sample Student *t* test: \**P* ≤ .05. (*D*) qRT-PCR shows increased Cyp7a1 expression in liver from *Gata4* cKI mice (*ROSA26*^*lnlG4/+*^*Villin-Cre*) compared with control mice (*ROSA26*^*lnlG4/+*^; n = 3 animals per genotype). Glyceraldehyde-3-phosphate dehydrogenase was used for normalization. Error bars represent SEM. \**P* ≤ .05.](gr10){#fig10}

![**Lactase protein is expressed in *Gata4* cKI ileum.** (*A*) Immunofluorescent staining showed Lactase protein (LCT, green) at the brush border in ileal epithelium of *Gata4* cKI mice, whereas LCT protein was absent from ileal epithelium of control mice. Sections from at least 3 control and 3 *Gata4* cKI animals were evaluated. E-cadherin (ECAD, red) was used to stain epithelial cell membranes. 4′,6-diamidino-2-phenylindole (DAPI) (blue) stained nuclei. *Scale bars*: 100 μm. (*B*) Immunoblot analysis of protein extracts from ileal epithelial cells of control and *Gata4* cKI mice was used to quantify LCT protein (n = 3). To quantify protein expression, signal was measured using quantitative infrared immunoblotting (LI-COR) and National Institutes of Health ImageJ software. *Arrowhead* indicates the LCT band measured. LCT protein levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. Molecular weight marker locations are indicated. Error bars show SEM. *P* values were determined by 2-sample Student *t* test: \**P* ≤ .05.](gr11){#fig11}

###### 

Primer and Oligo sSquences for pBigT-*Gata*4, Southern Probes, Genotyping, RT-PCR, bio-ChIP-PCR, and EMSA

Table 1

  Gene                           Forward                         Reverse                         Size, *bp*
  ------------------------------ ------------------------------- ------------------------------- ----------------
  **pBigT-*Gata4* Generation**                                                                   
  *Gata4cds*                     TACTCGAGGGGGCGATGTACCAAAGCCTG   ATGAGCTCTTACGCGGTGATTATGTCCCC   1348
  **Southern probes**                                                                            
  pROSA26 5' probe               CTCTGGCTCCTCAGAGAGCCTC          TCCGGCTGTCTCACAGAACGGC          137
  **Genotyping**                                                                                 
  *ROSA26*^*Gata4*^              AAAGTCGCTCTGAGTTGTTAT           GCGAAGAGTTTGTCCTCAACC           311, transgene
                                 AAAGTCGCTCTGAGTTGTTAT           GGAGCGGGAGAAATGGATATG           603, wt
  *VillinCre*                    CAAGCCTGGCTCGACGGCC             CGCGAACATCTTCAGGTTCT            ∼350
  *Gata4*^*loxP*^                CCCAGTAAAGAAGTCAGCACAAGGAAAC    AGACTATTGATCCCGGAGTGAACATT      355, wt
                                                                                                 455, loxP
  *Gata4 Exon7*                  CAGTGCTGTCTGCTCTGAAGCTGT        CCAAGGTGGGCTTCTCTGTAAGAAC       378, wt
                                                                                                 550, flagbio
  *BirAJax 14/15*                TTCAGACACTGCGTGACT              GGCTCCAATGACTATTTGC             500
  *BirAJax 16/17*                GTGTAACTGTGGACAGAGGAG           GAACTTGATGTGTAGACCAGG           400, wt
  **RT-PCR**                                                                                     
  *Aadac*                        GGCTTAGCCCCAAAACACCA            CAAGAGCCTGAAGGGCAGGA            241
  *Abi3bp*                       ATGAAACATTGGCTTTACCAGCAGA       AAAGCACTAGACAGGGTGGGCTTAG       124
  *Acot12*                       ACCACAAGATCTCACAGCCCTACTG       ACTCATCAGGTTTTAGCCCACCATT       188
  *Asah2*                        TGGCCATTTTTGCCATAGCC            ACCACTCTGGGCTCCACGAC            161
  *Cd74*                         GGCTTGAGACTGGTGTCTGTTTCAT       GAAATGGGGGTTCCCTTTAGATAGC       115
  *Dfna5*                        TGGGAAACCAGAAATGCTACTTGAG       CACTGGAATTGCCCCAGACATAATA       150
  *Dnase1*                       TGGCTGTGAACCCTGTGGAA            GTCCTCCAGGCCCCACTTTT            190
  *Enpp7*                        CATGGTGAAGCAGGTAGACAGGACT       AGTCCAACAGCTCAAACTGGATGTC       197
  *Ereg*                         TGTTTTGACCTCAAAGCTGGGAATA       TTTTAAAACATGTTCACCCGACACC       151
  *Gapdh*                        GATGCCCCCATGTTTGTGAT            GGTCATGAGCCCTTCCACAAT           150
  *Nos2*                         CTCAGCCCAACAATACAAGATGACC       TGTGGTGAAGAGTGTCATGCAAAAT       184
  *Pik3ap*                       ATGCGACATCCTCATCTTCTACAGC       GTATGTCTGCGTCTTCTGGCTACGA       109
  *Prss23*                       AGGGCTGGAGAATGGCTAAGTAGTG       GCAAGGACCATCAGTCCTCCTATCT       144
  *Rragd*                        AGTGATCAAAGGTGAACACCACCAT       TGGGAGGCTCAATCTTACATTTCAA       103
  *Slc23a1*                      TGGATTCCAACCCAGGTGCT            TACCATGCCCATCCCAAAGG            236
  *Slc25a48*                     CTTTAAGGTGTTTTTCAGGGGCATC       TCCTGATACCTCATTCGCTTCTCAC       140
  *Tmigd1*                       TTTTGCATCAAGACCATCTCGATTT       TTTCTATTCTGAACCCTTGCCCATT       180
  **bio-ChIP-PCR**                                                                               
  *Aadac* bs                     AGCTGAGCTGTGAACAGAAAGGAAC       TTCAATGGCTCGGCTTATGAAGTAG       101
  *Abi3bp* bs                    TGGATTCTTATCTGGGGTGGCTTAT       AAGTCTTCCCAGAGGACTCGTGTTT       145
  *Acot12* bs                    AGGAGAGCTGTCTGTGCCTCTTTCT       CTCCAACAGATCGTTGATGGGATAG       183
  *Asah2*\_1 bs                  TCTCCTGGCCATGTTTGGTCTACTA       AGGGATGGTGAGGGTAAGATTTTCA       165
  *Asah2*\_2 bs                  AGGACAGCTGCCTTATCTTATCCTT       AAAACCACCCAAACATTATAGCTG        109
  *Alb* nc                       TACTTAACATAGGGACGAGATGGTA       CATACTAAACGTAGACAAGTTGGCC       221
  *Cd36* bs                      GCCACACTGTCGTAAGGAGTATTGG       TTTTGCACATTAATCCCTTCGTGAT       100
  *Cd74* bs                      AGCCTCTAATCTGGAAAAGGGTTCC       GCAGCTCTCTTCCCCTACACACATA       197
  *Cdk4* nc^46^                  CATACAGTGGCTTATTATATTTCC        CTCCACCGCCATGGGGAAACATTC        259
  *Dfna5* bs                     CCCACTTCCTTGTCAACAATGTCTC       TTTCTTGGCTGATGCTATGGTTTGT       126
  *Dll1* nc                      TGGCAAGGGAGAGAAGGAAGCA          ACAGCCTTGGTCTGTTCAGTGT          158
  *Dnase1* bs                    GTGGCCATGAGTCATCCGTCTA          GAGGGAAAGGCTTCCCACAGAT          146
  *Enpp7* bs                     TAAAAGCCATCCCAGCATCACA          CAAAGTCCCAGGGTCAGACAGG          108
  *Ereg* bs                      CAGGAAAGAGAGTGAAGCGAGTGAG       GAATGAAGTTTCAATGCAGCTCCTG       192
  *Fabp1* bs                     TATCTCTTTCGGTCTGGTTGCACTC       AGAGAGGCCATTATGTGAAGCTGTG       123
  *Fabp6* bs                     AGAGTTCTGGGCCAATCTGGTCTAC       TGAGTTACATTAAATGCTCAGCTGCTT     112
  *Fgf15* bs                     CCAGTTGTCCATATGAATTCTCCA        GGCTGATGGCACTGAGACAGAG          118
  *Hprt* nc                      AGCGCAAGTTGAATCTGC              AGCGACAATCTACCAGAG              219
  *Hsd17b6* bs                   GAAATCGGAGATTTGAGGTCACTTG       CAGAACTATCCCGCTCCTCTTTCTC       104
  *Il33* bs                      TCTCTGTTTCTGAGGGGAACCAA         CATCGACCAAGACTGTCAGCATC         183
  *Lct* bs                       CTGGCAGCGCATGATTAAGTTG          TGGGAGGCAGTCTTCATTGTGA          199
  *Mep1a* bs                     TCCCTTTGGGTAGCCTGAATGA          TCGTGGTGACTCCCAACCATAA          148
  *Prss23* nc                    AGATGATTGATCGGGGCTTTCA          GGTAGAGGCAGCAGGCAACAAG          106
  *Prss23* bs                    ATGGCCAAGGCAACTTAGAGAAGAG       TTTGTGCTTGGGATTTAAGGTCTGA       122
  *Rnf180* bs                    CTGGAGCTCAACTGTACCACAGGAT       AAGCAATCCCTGCAGGAAAATAGAC       173
  *Slc10a2*\_1 bs^38^            GAATTAAGCCCAACCACACAGT          TTTTAACCCCGTCTTTCCTCTACT        150
  *Slc10a2*\_2 bs^38^            GTACAATGATGGGCTGAATGGG          CTCAGATACTTTAACCCACAGGCA        201
  *Slc10a2* nc                   GGTCTGTTAAACAAAGGGCAAACAA       AGCTCAGTGTTCACCCAACCAGATA       133
  *Slc23a1* bs                   TCCTGAAGAGCAGCAATGGTGA          GGGCCAGAGTCTACAGGGTGAA          143
  *Slc25a48* bs                  GATTCATTCCTGGAGGAGGAAAATG       GTTGGGGTGTCATCTTGCTAACCTT       141
  *Sqrdl* bs                     CAGCTGCTTCTGGTAATGAGTGACA       CACAGGACCAATCTTGTTTTCCATC       140
  *Suox* bs                      ATCAGGTAGGTTTTCCCAAGCCAGT       TGGCTTTCTCTTTCCTCCAATACTGT      122
  *Tmigd1* bs                    TTAATAAGCCTCTCAGGTGGCTGTG       GCAGTGCTAGATCCTTCCCTTTGAT       135
  *Ugt2a3* bs                    AACTCTCTTGAGCTCCGTGTCTTTG       GTTTCGCAAAGATTGAGGGTTTGTT       104
  *Ugt2a3* nc                    GAATCAGAGAGGCAAAATGAAGTCC       AAATCATGTTGCATTCCATTGATATTT     143

  Gene              ID                               Gene                ID
  ----------------- -------------------------------- ------------------- --------------------------------
  **TaqMan**                                                             
  *Akr1b8*          Mm00484314_m1                    *Lactase*           Mm01285112_m1
  *Cck*             Mm00446170_m1                    *Mep1a*             Mm00484970_m1
  *Cd36*            Mm01135198_m1                    *Pdx1*              Mm00435565_m1
  *Cyp7a1*          Mm00484150_m1                    *Rnf180*            Mm01304501_m1
  *Fabp1*           Mm00444340_m1                    *Slc10a2*           Mm00488258_m1
  *Fabp6*           Mm00434316_m1                    *Sqrdl*             Mm00502443_m1
  *Fgf15*           Mm00433278_m1                    *Sst*               Mm00436671_m1
  *Gapdh*           Mm99999915_g1                    *Suox*              Mm00620388_g1
  *Gata4*           Mm00484689_m1                    *Trpm6*             Mm00463112_m1
  *Gata6*           Mm00802636_m1                    *Ugt2a3*            Mm00472170_m1
  *Hsd17b6*         Mm00457343_m1                                        
  **EMSA Probes**                                                        
  *Lct*             CATTGTGATAAGATAAAGCTGT           *Lct* Mutant        CATTGTCGGTGCGGTAAGCTGT
  *Cd36*            TTAGATAAGATTATAGTATGTT           *Cd36* Mutant       TTACGGTACGGTTCCGCATGTT
  *Fgf15*           GAACTGTAGATAAACACAGG             *Fgf15* Mutant      GAACTGGCCGGTCACACAGG
  *Fgf15_2*         AGGCTCTGATAACAGGCTAA             *Fgf15*\_2 Mutant   CGGCTCTCGGTGCAGGGCCA
  *Slc10a2*         AACTGATGATAAGTTGGCTGCTTATCAAGC   *Slc10a2* Mutant    AACTCGGCGGTGCTTGGCTGCCACCGAAGC
  *xiFABP*          GGAGATCCCTGTACAGATATGGGGAGAC                         

bs, binding site; nc, negative control.

###### 

Antibodies

  Antibody                                                       Dilution   Manufacturer                               Catalog number
  -------------------------------------------------------------- ---------- ------------------------------------------ ----------------
  Immunohistochemistry and immunofluorescence                                                                          
   GATA4 C-20 (goat polyclonal)                                  1:250      Santa Cruz Biotechnology, Santa Cruz, CA   sc-1237
   ASBT/SLC10A2 (rabbit polyclonal)                              1:4000     Gift from Paul Dawson                      
   LCT T-14 (goat polyclonal)                                    1:50       Santa Cruz Biotechnology                   sc-240614
   ECAD (mouse polyclonal)                                       1:4000     BD Transduction Laboratories               610181
   Biotinylated rabbit anti-goat (heavy and light chains) IgG    15 μl/mL   Vector Labs                                BA-5000
   Biotinylated goat anti-rabbit (heavy and light chains) IgG    15 μl/mL   Vector Labs                                BA-4000
  Immunoblotting                                                                                                       
   GATA4 C-20 (goat polyclonal)                                  1:1000     Santa Cruz Biotechnology                   sc-1237
   TATA binding protein                                          1:1000     Abcam, Cambridge, MA                       ab818
   ASBT/SLC10A2 (rabbit polyclonal)                              1:1500     Gift from Paul Dawson                      
   OSTα                                                          1:1000     Gift from Paul Dawson                      
   OSTβ                                                          1:1000     Gift from Paul Dawson                      
   LCT T-14 (goat polyclonal)                                    1:1000     Santa Cruz Biotechnology                   sc-240614
   IRDye 800CW donkey anti-goat IgG (heavy and light chains)     1:15,000   LI-COR Biosciences                         926-32214
   IRDye 680RD donkey anti-mouse IgG (heavy and light chains)    1:15,000   LI-COR Biosciences                         926-68072
   IRDye 800CW donkey anti-rabbit IgG (heavy and light chains)   1:15,000   LI-COR Biosciences                         926-32213

###### 

Duodenal- and Jejunal-Enriched Transcripts With Increased Expression and Ileal-Enriched Transcripts With Decreased Expression in GATA4+ Ileum

  Duodenal/jejunal transcripts increased in GATA4+ ileum             
  ----------------------------------------------------------- ------ --------
  *Fabp1*[a](#tbl3fna){ref-type="table-fn"}                   6.03   292.04
  *Lct*[b](#tbl3fnb){ref-type="table-fn"}                     6.93   140.53
  *Cd36*[a](#tbl3fna){ref-type="table-fn"}                    2.87   45.39
  *Dnase1*[b](#tbl3fnb){ref-type="table-fn"}                  2.93   38.10
  *Enpp7*[b](#tbl3fnb){ref-type="table-fn"}                   2.98   33.69
  *Hsd17b6*[a](#tbl3fna){ref-type="table-fn"}                 3.25   27.78
  *Slc23a1*[b](#tbl3fnb){ref-type="table-fn"}                 2.79   25.06
  *Aadac*[a](#tbl3fna){ref-type="table-fn"}                   3.74   24.56
  *Ugt2a3*[a](#tbl3fna){ref-type="table-fn"}                  3.37   23.52
  *Acot12*[a](#tbl3fna){ref-type="table-fn"}                  3.28   18.37
  *Gata4*[a](#tbl3fna){ref-type="table-fn"}                   2.61   15.24
  *Asah2*[b](#tbl3fnb){ref-type="table-fn"}                   3.00   14.75
  *Gstm3*[a](#tbl3fna){ref-type="table-fn"}                   2.75   8.55
  *Il33*[b](#tbl3fnb){ref-type="table-fn"}                    2.79   7.95
  *Rragd*[b](#tbl3fnb){ref-type="table-fn"}                   2.21   7.89
  *AY761184*[a](#tbl3fna){ref-type="table-fn"}                2.18   2.78
  *Gm10409/Gm3020/Gm3194*[b](#tbl3fnb){ref-type="table-fn"}   2.28   2.34

                      Duodenal fold enrichment
  ------------ ------ --------------------------
  *Cd59a*      2.19   7.49
  *Slc16a12*   2.11   6.22
  *Lmcd1*      2.07   5.30
  *Akr1b8*     2.47   3.32

  Ileal transcripts decreased in GATA4+ ileum           
  --------------------------------------------- ------- ---------
  *Fabp6*                                       -3.35   -310.51
  *Slc10a2*                                     -3.26   -112.94
  *Tmigd1*                                      -3.51   -26.15
  *Suox*                                        -3.53   -24.13
  *Nos2*                                        -2.14   -13.47
  *Slc25a48*                                    -3.63   -11.92
  *Scd1*                                        -3.84   -6.30
  *Sqrdl*                                       -2.32   -5.87
  *Dfna5*                                       -2.05   -4.54
  *Bex1*                                        -2.03   -4.41
  *Prss23*                                      -2.45   -4.39
  *Mep1a*                                       -2.05   -4.33
  *Ly6a*                                        -2.65   -4.18
  *Mfhas1*                                      -2.69   -3.99
  *Pik3ap1*                                     -2.17   -3.90
  *Rnf180*                                      -2.77   -3.72
  *Abi3bp*                                      -4.13   -3.67
  *Trpm6*                                       -2.53   -3.64
  *Ereg*                                        -2.01   -3.52
  *Fgf15*                                       -5.56   -3.42
  *Acta2*                                       -2.76   -3.10
  *Ebf1*                                        -2.08   -2.58
  *Marcksl1*                                    -2.07   -2.30
  *Cd74*                                        -2.02   -2.30
  *Cd53*                                        -2.62   -2.20
  *Mapk4*                                       -2.04   -2.15
  *Dcn*                                         -2.34   -2.15
  *Nlrc5*                                       -2.15   -2.09
  *Ighv1-63*                                    -2.52   -2.07

Jejunal/duodenal-enriched transcripts (equivalently expressed between duodenum and jejunum).

Jejunal-enriched transcripts.

###### 

High-Confidence GATA4 Regulated Targets

  Jejunal-enriched transcripts          
  ------------------------------ ------ --------
  *Lct*                          6.93   -19.17
  *Fabp1*                        6.03   -10.84
  *Aadac*                        3.74   -2.76
  *Ugt2a3*                       3.37   -2.89
  *Acot12*                       3.28   -3.75
  *Hsd17b6*                      3.25   -18.32
  *Asah2*                        3.00   -3.31
  *Enpp7*                        2.98   -6.80
  *Dnase1*                       2.93   -17.57
  *Cd36*                         2.87   -29.24
  *Slc23a1*                      2.79   -15.73
  *Il33*                         2.79   -5.02

  Ileal-enriched transcripts           
  ---------------------------- ------- --------
  *Fgf15*                      -5.56   8.48
  *Abi3bp*                     -4.13   10.40
  *Slc25a48*                   -3.63   7.38
  *Suox*                       -3.53   22.73
  *Tmigd1*                     -3.51   23.35
  *Fabp6*                      -3.35   308.59
  *Slc10a2*                    -3.26   80.81
  *Rnf180*                     -2.77   3.32
  *Prss23*                     -2.45   4.77
  *Sqrdl*                      -2.32   4.83
  *Dfna5*                      -2.05   2.79
  *Mep1a*                      -2.05   4.68
  *Cd74*                       -2.02   2.07
  *Ereg*                       -2.01   2.72
